Figure 5.

Effect of IU1 on COPS5-Induced Downstream Effectors In Vivo and In Vitro

(A and B) Expression and association of p53, USP14, and COPS5 in primary tumor tissues from p53^−/− mice treated with DMSO (A; Ctrl, n = 28) or IU1 (B; n = 28). (C) Western blotting was used to measure the protein level of USP14, COPS5, and COPS5 downstream effectors in homozygous p53^−/− mice. (D–F) Western blotting was used to measure the protein levels of USP14, COPS5, and COPS5 downstream effectors in PCOC and MTLTC cells with treatment of IU1 (D), knockdown (E), or overexpression (F) of USP14. (G–I) Bar graphs (mean ± SD) show percentage of AnxV⁺ cells treated with IU1 treatment with or without COPS5 overexpression (G), USP14 knockdown with or without COPS5 overexpression (H), and USP14 overexpression with or without COPS5 knockdown (I). (J–L) Viability was measured in PCOC and MTLTC cells treated with IU1 treatment with or without COPS5 overexpression (J), USP14 knockdown with or without COPS5 overexpression (K), and USP14 overexpression with or without COPS5 knockdown (L). Data shown are the mean ± SD. Statistical analyses were performed with one-way ANOVA (*p < 0.05 and **p < 0.01 versus control).